Future Directions in Regenerative Medicine

Big Pharma has begun investing in regenerative medicine: Genzyme in 2008, Pfizer and Novartis in 2009, and Cephalon in 2010. In 3-5 years, investment will reach a “tipping point”, after which no medical industry players will want to be left behind. This report covers the development of therapies to replace human cells or promote their regeneration: including cell therapies, tissue engineering, drugs, and medical devices. Each company profiled has at least one project in preclinical or Phase I study. Many also have later stage or launched products, which are covered briefly to illustrate the potential of the next generation of candidates. This report will enable you to:- Understand the concepts behind regenerative medicine, its potential applications, and advantages over traditional medicine. - Compare the opportunities and challenges presented by the different therapeutic modalities. - Understand the hurdles that must be overcome by regenerative medicine candidates before they can successfully enter the market. - Identify emerging technologies that will shape the regenerative medicine industry in the coming years. - Identify companies that may be competitors for a market, or alternatively potential partners or investment opportunities.